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Abstract
Purpose
To evaluate the potential role of 18F-fluorodeoxyglucose-positron emission tomography/
computerized tomography (FDG-PET/CT) for predicting treatment response after radiother-
apy (RT) in patients with spinal metastases.
Materials and methods
A retrospective analysis was performed of 42 patients with spinal metastases who received
RT from January 2010 to December 2014. All patients underwent FDG-PET/CT before and
after treatment. Changes in metabolic responses, expressed as the maximum, mean, peak
standardized uptake values (SUVmax, SUVmean, SUVpeak), metabolic tumor volume
(MTV) and total lesion glycolysis (TLG) were analyzed to determine their association with
clinical outcomes.
Results
The median age at the time of spinal metastasis diagnosis was 58 years. Median progres-
sion-free survival (PFS) and overall survival after RT were 15 months and 22.4 months,
respectively. RT produced a significant decrease in SUVmean (2.27 to 1.41), SUVmax
(6.87 to 2.99), SUVpeak (5.75 to 2.33) and TLG (52.84 to 24.17) when compared with the
baseline values (p<0.001). The mean pain score decreased from 3.86 before RT to 0.79
after RT (p<0.001). There were significant linear relationships between maximum SUV and
pain scores at baseline (r = 0.321, p = 0.038) and after treatment (r = 0.369, p = 0.016) as
well as TLG at baseline (r = 0.428, p = 0.005) and after treatment (r = 0.403, p = 0.009).
Local progression after treatment was identified in 12 patients (28.6%). Univariate analyses
showed that >70% reduction in maximum SUV after treatment was independently associ-
ated with good PFS (p = 0.036).
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Conclusions
RT is an effective treatment for patients with spinal metastases, and there were significant
changes in PET parameters compared with baseline. The metabolic response measured by
SUV and TLG changes in FDG-PET/CT correlated with the clinical outcomes, especially
with shorter PFS in patients who had higher residual maximum SUV after treatment.
Introduction
The spine is the most frequent bone metastatic site, and spinal metastases have been reported
in approximately 5% to 14% of all cancer patients [1]. Spinal metastases often cause severe
morbidity and adversely affect quality of life because of pain, pathologic fractures, and spinal
cord compression [2, 3]. Treatment options for spinal metastases include surgery, radiother-
apy (RT), and systemic therapy, such as bisphosphonates; the goal of these modalities is pallia-
tion of pain, maintenance of spinal stability, prevention of neurologic deficit, and slowing of
local disease progression [4, 5]. RT, the most common strategy for spinal metastases, has been
reported to provide significant palliation of pain in approximately 60% to 90% of patients,
with up to 33% of individuals achieving complete pain response at the irradiated site [4, 6, 7].
As the life expectancy of patients with successful treatment of spinal metastases is increasing,
proper assessment of treatment response is essential for making correct treatment decisions
and improving outcomes.
Imaging of tumor metabolism with 18F-fluorodeoxyglucose-positron emission tomogra-
phy/computerized tomography (FDG-PET/CT) has been widely applied in the evaluation of
various malignancies. Changes in tumor glucose utilization provide quantitative and qualita-
tive functional information [8]. 18F-FDG-PET/CT has been proven useful in assessing progno-
sis and monitoring treatment outcomes, and a number of studies have shown that PET
parameters correlate with radiologic response in several tumor types [9–11]. However, few
studies have reported the prediction power of 18F-FDG-PET/CT in patients who received RT
for spinal metastases [12, 13].
The aim of this study is to assess the role of metabolic monitoring by 18F-FDG-PET/CT for
predicting treatment response after RT in patients with spinal metastases. We evaluated
whether changes in PET parameters including the standardized uptake value (SUV) and total
lesion glycolysis (TLG) after treatment are correlated with clinical results.
Materials and methods
Patients
A total of 42 patients with spinal metastases who received RT from January 2010 to December
2014 were evaluated. We retrospectively reviewed the medical records of these patients and
collected data regarding their sex, age, clinical presentation, primary cancer, radiologic fea-
tures, presence of metastases at other sites, type of treatment, and clinical course. All patients
underwent physical examination including neurologic assessments at baseline and 1, 3, and 6
months after RT. Pain intensity at the treatment site was evaluated every assessment day using
the Brief Pain Inventory, which assesses pain at its “worst,” “least,” “average,” and “now” (cur-
rent pain). In our institution, “worst” was used to represent pain severity experienced for pre-
vious 24 hours by the numeric rating scale, in which 0 = no pain to 10 = worst pain
imaginable. Characteristics of the spinal metastases, such as the involved segment or the
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presence and location of a pathologic fracture or cord compression, were obtained using imag-
ing studies, including plain radiography, computed tomography (CT), and magnetic reso-
nance imaging (MRI). All patients underwent FDG-PET/CT prior to treatment and after
treatment. This Institutional Review Board of the Severance Hospital, Korea (IRB No. 3-2011-
0281) approved this retrospective study in accordance with ethical guidelines and the Declara-
tion of Helsinki. The consent was not necessary, because patient records and information were
anonymized and de-identified prior to analysis.
Radiotherapy and response assessment by FDG-PET/CT
Each patient underwent CT-based simulation, and structures were manually contoured on CT
scan slices. The planning target volume included the specific vertebral body affected, with 0 to
1 cm extension around the clinical target volume. RT was given once per day with 3-dimen-
sional conformal RT, intensity-modulated RT, or stereotactic body RT. Patients received radi-
ation at a dose of 20–54 Gy in 3–30 fractions. The median total dose, which was converted to
the biologically effective dose (BED), was 50 Gy10.
All 18F-FDG-PET/CT data obtained before and after treatment for each patient were trans-
ferred to MIMvista (MIM Software, Inc., USA) for objective comparisons. A region of interest
was drawn with a 5-cm diameter where the lesion appeared to have the largest uptake at base-
line. The same site was identified on the post-treatment image, even when there was a com-
plete response. To evaluate the metabolic response, the SUVmean, SUVmax, maximum
average SUV within a 1-cm3 spherical volume (SUVpeak), metabolic tumor volume (MTV)
and TLG were measured at the region of interest. We defined MTV as total tumor volume
with a SUV of 2.5 or greater, and TLG as the product of SUVmean and MTV. The percentage
reduction in SUVmax between before and after RT was calculated as follows: % reduction = 100
× (pre-RT SUVmax − post-RT SUVmax)/pre-RT SUVmax.
Statistical analysis
The primary endpoint was the response rate of patients who had decreased SUV values (deter-
mined by 18F-FDG-PET/CT) after treatment, compared to baseline. Differences between pre-
and post-treatment values of PET parameters were compared using the paired t-test. Based on
the PET Response Criteria in Solid Tumors (PERCIST) criteria [14], complete metabolic
response (CMR) was defined as normalization of all lesions (target and non-target), so that the
SUV corrected for the lean body mass (SUL) is less than mean liver SUL and equal to SUL of
the normal surrounding tissue. Partial metabolic response (PMR) was defined as> 30%
decrease in SUL peak with a minimum 0.8 unit decrease. Progressive metabolic disease (PMD)
was defined as a> 30% increase in SUL peak with a minimum 0.8 unit increase in SUL peak,
or the presence of new lesions. Stable metabolic disease (SMD) was disease that did not meet
the CMR, PMR, or PMD criteria. Patients with a CMR or PMR were defined as responders,
and patients with SMD or PMD as non-responders. This study was designed to assess whether
metabolic monitoring with FDG-PET/CT after RT could predict the time to local progression
or death. Recurrence or progression at the treatment site defined with CT or MRI-based fol-
low-up imaging studies. The imaging findings compared to previous studies had reviewed by
radiologists. In case of new lesions developed other than treatment site, we excluded them
from analyzing progression-free survival (PFS) in this study. PFS and overall survival (OS)
were measured from the date of starting RT to the date of documented progression, death, or
last follow-up. Survival data were analyzed using the Kaplan-Meier method, and comparisons
performed using a two-sided log-rank test. The Spearman correlation test was used to deter-
mine the association between PET parameters and pain scores. Statistical analyses were
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The patients’ median age at the time of spinal metastasis diagnosis was 58 years (range, 24–80
years). Overall, 69% of patients (n = 29) were female, and 54.8% (n = 23) had distant metastasis
in addition to the spinal involvement. The most common primary cancer was breast cancer
(n = 18), followed by hepatobiliary cancer (n = 10). The treated segment was located in the tho-
racic spine in 27 patients, lumbar spine in 23 patients, and cervical spine in eight patients.
Cord compression on imaging studies was present in 19% of patients. The most frequent extra-
osseous organ system with a metastasis was the lung, and control of the distant metastases was
maintained in 43% of patients. The mean pain score prior to treatment was 3.86 (range, 0–10).
Detailed information regarding patient characteristics is presented in Table 1.
Table 1. Baseline characteristics and treatment of the 42 patients.
Characteristic Number of patients, median, or mean Percentage (%) or range
Age, years








Head and neck 4 9.5
Others 5 11.9
Treatment segment
Cervical spine 8 13.8
Thoracic spine 27 46.6















Mean (range) 3.86 0–10
RT, radiotherapy; 3D-CRT, 3-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; SBRT,
stereotactic radiotherapy
https://doi.org/10.1371/journal.pone.0204918.t001
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Measurement of therapeutic response by FDG-PET
RT resulted in a significant decrease in all PET parameters except MTV when compared with
baseline values (Table 2). The SUVmax and SUVmean (mean ± standard deviation) were
6.87 ± 0.88 and 2.27 ± 0.2 at baseline, respectively, 2.99 ± 0.2 and 1.41 ± 0.07 after treatment,
respectively (p< 0.001). The TLG (mean ± standard deviation) was 52.84 ± 7.19 at baseline
and 24.17 ± 3.67 after treatment (p< 0.001). According to the PERCIST criteria using the
change in SUV from baseline to after treatment, FDG-PET revealed a PMR in 28 patients
(66.7%), SMD in seven patients (16.7%), and PMD in one patient (2.3%). CMR was observed
in six patients (14.3%; Fig 1). Overall, 81% of patients were responders, with a metabolic
tumor response (CMR or PMR). As shown in Fig 2, there was a significant linear relationship
between the SUVmax and pain scores at baseline (r = 0.321, p = 0.038) and after treatment
(r = 0.369, p = 0.016) as well as TLG at baseline (r = 0.428, p = 0.005) and after treatment
(r = 0.403, p = 0.009). The mean pain score decreased from 3.86 before treatment to 0.79 after
treatment (p< 0.001). No significant radiation dose effect was observed after analysis on pain
and PET response according to BED.
Prediction of progression-free survival
The median PFS and OS after the start of RT were 15 months (range, 3.6–56.6 months) and
22.4 months (range, 3.6–61.3 months), respectively. Univariate analysis was performed using
the variables listed in Table 3, which have been previously suggested to be associated with PFS.
Only a reduction in SUVmax was identified as a potential predictor of local progression.
Patients with more than 70% reduction in SUVmax between pre- and post-treatment PET
studies had better PFS (p = 0.036). There was a trend toward shorter survival in patients with a
higher residual SUVmax after treatment (p = 0.08; Fig 3).
Discussion
Spinal metastases are frequently encountered during the course of malignancy, even in cancers
with a poor prognosis [15]. In general, patient survival is highly dependent on the primary
tumor; a previous study reported that the median OS after RT for bone metastases was 16
months for patients with breast cancer and 9.5 months for patients with prostate cancer [16].
Because of the effectiveness of RT for pain and neurological symptoms, RT remains the cor-
nerstone of treatment of spinal metastases [15, 17]. In the current study, the median OS and
local PFS were improved after RT to 22.4 months and 15 months, respectively, despite the
patients exhibiting heterogeneous primary tumors. The mean pain score also decreased signifi-
cantly with RT, from 3.86 to 0.79. Previous studies have suggested the histology of the primary
Table 2. 18F-fluorodeoxyglucose-positron emission tomography parameters at baseline and after treatment.
Parameter Pre-treatment Post-treatment p
Mean SD Mean SD
SUVmax 6.87 0.88 2.99 0.20 <0.001
SUVmean 2.27 0.20 1.41 0.07 <0.001
SUVpeak 5.75 0.73 2.33 0.16 <0.001
MTV 12.06 1.55 12.04 1.48 0.976
TLG 52.84 7.19 24.17 3.67 <0.001
SUV, standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis
Data are mean ± standard deviation (SD).
https://doi.org/10.1371/journal.pone.0204918.t002
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tumor, a good performance status, and the absence of visceral metastases as prognostic factors
predicting OS and PFS in patients who received RT for spinal metastasis from various malig-
nancies [18–21]. With advances in oncology and the successful treatment of metastatic spinal
cord tumors, we expect patients with spinal metastases to live longer. Consequently, a method
is required that can estimate their expected survival and help in the selection of successful
treatment.
A variety of approaches to measure response rates and PFS have been developed, including
the World Health Organization criteria and the Response Evaluation Criteria in Solid Tumors
(RECIST) [22]. The response rate typically refers to how frequently a tumor shrinks anatomi-
cally; however, lack of progression may be associated with good improvement in outcomes,
even in the absence of major tumor shrinkage [23]. Despite effective treatment, changes in
tumor size can be minimal in spinal metastases, as the changes depend on the type of metasta-
sis (e.g., whether it is lytic or sclerotic). To determine whether there is a lack of progression by
changes in tumor size requires regular and systematic assessment of tumor burden, and PET
characteristics appear more informative than CT or MRI in such cases [24]. To overcome this
drawback, the PERCIST criteria that integrate metabolic tumor response (i.e., PET) assessment
have been proposed. The PERCIST criteria used in this study include assessing the normal ref-
erence tissue values in the liver, determining the SUV in a fixed small region of interest in the
most active region of metabolically active tumors, and requiring a 30% or greater decline in
SUV for a “response” (PMR or CMR) [22]. However, the PERCIST criteria may be limited
when assessing the activity of lesions with an initially low SUV value. As shown in Fig 1,
among six patients with a CMR, one patient showed less than 70% reduction in SUVmax
because the initial SUVmax value was approximately 5. Indeed, all patients with SMD except
one had an initial SUVmax of approximately 3 to 4; it is difficult to expect a major reduction
in SUV in these cases. Conversely, even PMR patients showed good PFS when they had more
than 70% reduction in SUVmax.
Fig 1. Metabolic response of the 42 patients. Based on the PERCIST criteria, there are some mismatches between metabolic response and SUV reduction in
case of an initially low SUV value. One patient with a CMR showed less than 70% reduction SUVmax because the initial value was about 5.
https://doi.org/10.1371/journal.pone.0204918.g001
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Recently, 18F-FDG-PET/CT is receiving attention for predicting the response to radiation,
as well as detecting radiographically occult distant metastases [25]. In various tumors, meta-
bolic reduction after treatment has been suggested to be of value in the assessment of treatment
response [26, 27]. Tateishi et al. [28] showed that an increased SUV change was a significant
predictor of response duration (relative risk, 2.4; p = 0.003). The cut-off points of SUV changes
that best predicted clinical outcomes were 60% to 64% in single institutional analyses [9, 29].
Regarding incorporating FDG-PET/CT into RT planning, Tralins et al. [30] applied boost
radiation to the increased FDG uptake area, thus achieving dose escalation. In addition, the
FDG-PET/CT target volume significantly predicted the time-to-progression of the tumor in
their series. The results from these studies thereby support the role of metabolic response to
radiation as a predictive marker; however, the role of changes in FDG-PET/CT in patients
Fig 2. The relationship between SUVmax and pain scores (a, b), TLG and pain scores (c, d). (a) at baseline (r = 0.321, p = 0.038), (b) after treatment (r = 0.369,
p = 0.016), (c) at baseline (r = 0.428, p = 0.005), and (d) after treatment (r = 0.403, p = 0.009).
https://doi.org/10.1371/journal.pone.0204918.g002
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with spinal metastasis is not well defined. To our knowledge, ours is the first report to deter-
mine whether changes in FDG-PET/CT after RT can predict clinical outcomes. Metabolic
response to RT, as measured by a change in SUV between baseline and post-treatment, was
predictive of PFS. Patients with 70% reduction in SUVmax demonstrated longer median
PFS than those with < 70% reduction (Fig 4). We also found that pain scores at baseline and
post-treatment correlated with PET parameters including TLG, and a higher residual SUV was
associated with relative resistance to pain relief. However, because MTV is a volume for a spe-
cific criterion, the fact that the pre-treatment values did not decrease significantly in this study
Table 3. Univariate analysis of variables associated with survival in patients with spinal metastasis.
Variable 2-year PFS 2-year OS
No. % p % p
Age 0.468 0.355
55 18 72.9 73.3
>55 24 70.7 86.4
Sex 0.581 0.744
Male 13 71.3 91.7
Female 29 72.3 77.8
Cord compression 0.852 0.958
Yes 8 75.8 87.5
No 34 70.8 79.5
CTx after RT 0.82 0.828
Yes 23 69.9 78.9
No 19 71.9 83.6
Other site mets 0.596 0.173
Yes 23 73.7 71.4
No 19 69.8 82.4
DM control 0.319 0.205
Yes 18 82.4 94.1
No 24 61 63.6
RT dose, BED10 0.656 0.658
50 Gy 22 68.8 85.2
>50 Gy 20 76.7 79.1
% of SUVmax reduction 0.036 0.08
70 33 63.7 75.7
>70 9 100 100
% of SUVmean reduction 0.103 0.184
60 36 66.9 75
>60 6 100 100
% of SUVpeak reduction 0.109 0.184
70 35 67.2 78
>70 7 100 100
% of TLG reduction 0.091 0.15
75 34 68.3 76.6
>75 7 100 100
PFS, progression-free survival; OS, overall survival; RT, radiotherapy; BED, biological equivalent dose; SUVmax,
maximum standardized uptake value; SUVmean, mean standardized uptake value; SUVpeak, peak standardized
uptake value; TLG, total lesion glycolysis
https://doi.org/10.1371/journal.pone.0204918.t003
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suggests that the metabolic activity of the part of the lesion is reduced rather than dramatically
reduced by RT can do.
Given that our study was retrospective, it has some inherent limitations. It was a single-cen-
ter study with a small number of patients, and the time interval from completion of RT to the
follow-up PET/CT was variable. We included patients who developed distant metastases to
organs other than the spine during the course of their disease, as well as patients with uncon-
trolled disease. The radiation dose can have a considerable effect on patient outcomes. How-
ever, because of the heterogeneity of dose profiles and techniques of RT, we did not identify
the radiation dose as a significant predictive factor in univariate analysis during the current
study. In addition, there was no significance on values of PET parameters between different
BED groups. We demonstrated a linear relationship between PET parameters and pain scores,
but the inclusion of asymptomatic patients at baseline may have limited the significance of our
results. At present, given the cost and mixed diagnostic performance results of PET/CT, there
is not enough evidence to support the routine use of PET/CT in monitoring spinal metastases
[31]. Therefore, finding the most useful predictors among the various PET parameters, includ-
ing the SUV cutoff point, remains to be prospectively validated in future studies involving a
large number of patients. In addition, further studies are required to determine the optimal
time interval between treatment and follow-up PET/CT evaluation, and whether the value of
PET may have an impact on therapeutic decision-making. As shown in the correlation analy-
sis, the correlation coefficient of TLG was significantly higher in clinical relevance than the
other parameters. This suggests that new parameters such as TLG, which are not traditionally
meaningfully analyzed as SUVs, can be a predictor of the patient’s prognosis, and the authors
believe that future prospective studies will clarify this point.
Conclusions
RT was an effective treatment for patients with spinal metastases. Pain relief generally occurred
after RT, and significant changes in PET parameters compared with baseline were detected. In
Fig 3. Kaplan-Meier survival curves for patients included in this study. (a) Progression-free survival and (b) overall survival for patients with more than 70%
reduction in maximum standardized uptake values versus those with less than 70% reduction.
https://doi.org/10.1371/journal.pone.0204918.g003
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addition, the metabolic response measured by SUV changes in FDG-PET/CT correlated with
clinical outcomes, especially with a shorter PFS in patients who had higher residual SUVmax
after treatment. Our results provide evidence that metabolic monitoring with FDG-PET/CT
allows the prediction of treatment response after RT in patients with spinal metastases.
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Fig 4. Use of FDG PET/CT to assess treatment response. (a) Complete response after RT with 94.4% reduction (39.79 to 2.23) in maximum standardized uptake
values and (b) Partial response with 60% reduction (5.87 to 2.35).
https://doi.org/10.1371/journal.pone.0204918.g004
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